Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Trevi Therapeutics Inc.

    NASDAQ: TRVI · Real-Time Price · USD
    5.62
    -0.04 (-0.71%)
    At close: Jun 27, 2025, 3:59 PM
    5.62
    0.00%
    After-hours: Jun 27, 2025, 04:34 PM EDT

    Trevi Therapeutics Statistics

    Share Statistics

    Trevi Therapeutics has 119.14M shares outstanding. The number of shares has increased by 37.26% in one year.

    Shares Outstanding

    n/a
    		 119.14M

    Shares Change (YoY)

    n/a
    		 37.26%

    Shares Change (QoQ)

    n/a
    		 8.19%

    Owned by Institutions (%)

    n/a
    		 78.68%

    Shares Floating

    n/a
    		 69.87M

    Failed to Deliver (FTD) Shares

    n/a
    		 564

    FTD / Avg. Volume

    n/a
    		 0.03%

    Short Selling Information

    The latest short interest is 7.02M, so 5.77% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 7.02M

    Short % of Shares Out

    n/a
    		 5.77%

    Short % of Float

    n/a
    		 6.69%

    Short Ratio (days to cover)

    n/a
    		 6.67

    Valuation Ratios

    The PE ratio is -8.69 and the forward PE ratio is -10.35. Trevi Therapeutics's PEG ratio is -0.14.

    PE Ratio

    n/a
    		 -8.69

    Forward PE

    n/a
    		 -10.35

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 2.6

    PB Ratio

    n/a
    		 4.18

    P/FCF Ratio

    n/a
    		 -10.87

    PEG Ratio

    n/a
    		 -0.14
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Trevi Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 10.41, with a Debt / Equity ratio of 0.01.

    Current Ratio

    n/a
    		 10.41

    Quick Ratio

    n/a
    		 10.41

    Debt / Equity

    n/a
    		 0.01

    Debt / EBITDA

    n/a
    		 -0.02

    Debt / FCF

    n/a
    		 -0.03

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,545,516.13

    Employee Count

    n/a
    		 31

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -30K

    Effective Tax Rate

    n/a
    		 0.06%

    Stock Price Statistics

    The stock price has increased by 92.86% in the last 52 weeks. The beta is 0.53, so Trevi Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.53

    52-Week Price Change

    n/a
    		 92.86%

    50-Day Moving Average

    n/a
    		 6.34

    200-Day Moving Average

    n/a
    		 4.59

    Relative Strength Index (RSI)

    n/a
    		 38.69

    Average Volume (20 Days)

    n/a
    		 1,745,727

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -51.52M

    Net Income

    n/a
    		 -47.91M

    EBITDA

    n/a
    		 -51.52M

    EBIT

    n/a
    		 -47.95M

    Earnings Per Share (EPS)

    n/a
    		 -0.47
    Full Income Statement

    Balance Sheet

    The company has 34.1M in cash and 1.03M in debt, giving a net cash position of 33.06M.

    Cash & Cash Equivalents

    n/a
    		 34.1M

    Total Debt

    n/a
    		 1.03M

    Net Cash

    n/a
    		 33.06M

    Retained Earnings

    n/a
    		 -287.05M

    Total Assets

    n/a
    		 107M

    Working Capital

    n/a
    		 98.75M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -38.26M and capital expenditures -35K, giving a free cash flow of -38.29M.

    Operating Cash Flow

    n/a
    		 -38.26M

    Capital Expenditures

    n/a
    		 -35K

    Free Cash Flow

    n/a
    		 -38.29M

    FCF Per Share

    n/a
    		 -0.38
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    TRVI does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for TRVI is $21, which is 270.4% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $21

    Price Target Difference

    n/a
    		 270.4%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 8
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 47.17

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist